Could a common mood drug slow Parkinson's? early trial hints at possibility
NCT ID NCT06099886
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether low-dose lithium aspartate (30-45 mg/day) could slow Parkinson's disease in 15 people diagnosed within the last 4 years. Researchers measured changes in brain scans and blood markers linked to disease progression. The goal was to see if lithium is safe and worth testing in larger trials, not to cure the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University at Buffalo
Williamsville, New York, 14221, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- High-Resolution brain scans aim to unmask Tau's role in Parkinson's
- Can brain stimulation sharpen Decision-Making in Parkinson's?
- Can Stem-Cell implants restore movement in Parkinson's?
- Wild blueberries put to the test for Parkinson's motor symptoms
- Could tailored brain stimulation quiet Parkinson's tremors more effectively?
- Zapping away tremors: scientists probe how electrical stimulation calms shaky hands